IFOSFAMIDE PHARMACOKINETICS AND NEUROTOXICITY

被引：49

作者：

LEWIS, LD

MEANWELL, CA

机构：

[1] UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV CLIN PHARMACOL,LONDON SE1,ENGLAND

[2] QUEEN ELIZABETH HOSP,W MIDLANDS CRC CLIN TRIALS UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND

来源：

关键词：

D O I：

10.1016/0140-6736(90)90054-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：175 / 176

页数：2

共 10 条

[1]

ARNDT CAS, 1988, CANCER RES, V48, P2113

[2]

CREAVEN PJ, 1974, CLIN PHARMACOL THER, V16, P77

[3]

GOREN MP, 1986, LANCET, V2, P1219

HEIM, ME ;

FIENE, R ;

SCHICK, E ;

WOLPERT, E ;

QUEISSER, W .

[5]

JUMA FD, 1978, CANCER CHEMOTH PHARM, V1, P229

[6]

LEWIS LD, IN PRESS BR J CLIN P

[7]

LIND MJ, 1989, CANCER RES, V49, P753

[8]

LIND MJ, 1989, BIOCHEM PHARMACOL, V11, P1835

[9]

MEARWELL CA, 1985, LANCET, V1, P406

[10]

PEARCEY R, 1988, CANCER CHEMOTH PHARM, V22, P353